We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+33.73%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.59B
AUM Growth
+$475M
Cap. Flow
-$61.5M
Cap. Flow %
-2.37%
Top 10 Hldgs %
31.64%
Holding
140
New
7
Increased
46
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
CVET
Covetrus, Inc. Common Stock
CVET
+$23.1M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$16.6M
3
CI icon
Cigna
CI
+$16.4M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$15M
5
TVTX icon
Travere Therapeutics
TVTX
+$9.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$44.7M
2
LOXO
Loxo Oncology, Inc
LOXO
+$33.8M
3
MOH icon
Molina Healthcare
MOH
+$18.2M
4
WCG
Wellcare Health Plans, Inc.
WCG
+$18M
5
BIIB icon
Biogen
BIIB
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Miscellaneous 1.82%
3 Consumer Staples 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
76
Rigel Pharmaceuticals
RIGL
$842M
$10.8M 0.42%
420,000
– –
DERM
77
DELISTED
Dermira, Inc.
DERM
$10.5M 0.4%
775,000
+258,000
+50% +$2.15M
TBIO
78
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$10.3M 0.4%
1,009,179
– –
QTTB icon
79
Q32 Bio
QTTB
$328M
$10.3M 0.4%
20,556
-4,444
-18% -$1.99M
ACRS icon
80
Aclaris Therapeutics
ACRS
$770M
$10.2M 0.39%
1,700,000
+370,600
+28% +$2.46M
FRPT icon
81
Freshpet
FRPT
$2.99B
$9.94M 0.38%
235,000
– –
ODT
82
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$9.84M 0.38%
445,000
– –
AXNX
83
DELISTED
Axonics, Inc. Common Stock
AXNX
$9.58M 0.37%
400,000
– –
CBAY
84
DELISTED
Cymabay Therapeutics
CBAY
$9.49M 0.37%
715,000
+101,396
+17% +$1.08M
NVCR icon
85
NovoCure
NVCR
$1.91B
$9.39M 0.36%
195,000
– –
CHRS icon
86
Coherus Oncology
CHRS
$198M
$9.14M 0.35%
670,000
– –
ASMB icon
87
Assembly Biosciences
ASMB
$535M
$8.86M 0.34%
37,500
– –
HRTX icon
88
Heron Therapeutics
HRTX
$59.9M
$8.55M 0.33%
350,000
-175,000
-33% -$4.58M
IFRX icon
89
InflaRx
IFRX
$296M
$8.5M 0.33%
225,000
+7,100
+3% +$265K
MYOV
90
DELISTED
Myovant Sciences Ltd.
MYOV
$8.29M 0.32%
347,500
– –
ACHN
91
DELISTED
Achillion Pharmaceuticals
ACHN
$7.99M 0.31%
2,700,000
+375,000
+16% +$921K
AGIO icon
92
Agios Pharmaceuticals
AGIO
$2.01B
$7.92M 0.31%
+117,500
New +$6.84M
MRSN
93
DELISTED
Mersana Therapeutics
MRSN
$7.36M 0.28%
56,000
+16,000
+40% +$2.01M
CMTA
94
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$7.18M 0.28%
275,000
– –
BLUE
95
DELISTED
bluebird bio
BLUE
$7.08M 0.27%
3,474
– –
FPRX
96
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$6.77M 0.26%
505,000
– –
SPRO icon
97
Spero Therapeutics
SPRO
$64.6M
$6.72M 0.26%
525,000
– –
CO
98
DELISTED
Global Cord Blood Corporation
CO
$6.49M 0.25%
925,000
– –
SYRE icon
99
Spyre Therapeutics
SYRE
$8.09B
$6.44M 0.25%
32,000
+6,000
+23% +$1.25M
CLVS
100
DELISTED
Clovis Oncology, Inc.
CLVS
$6.35M 0.25%
256,000
– –
2 3
4
5 6

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Rock Springs Capital Management held 140 positions worth $2.59B, up 22% from $2.12B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rock Springs Capital Management's Q1 2019 filing shows 7 new, 46 increased, 13 reduced and 9 closed positions. Its largest new stake was Covetrus, Inc. Common Stock: 650,000 shares worth $20.7M. The largest sale was TESARO, Inc., an estimated $44.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Rock Springs Capital Management's largest Q1 2019 buy was Covetrus, Inc. Common Stock: 650,000 shares worth $20.7M.
  • Rock Springs Capital Management added most to Portola Pharmaceuticals, Inc. in Q1 2019, an estimated $16.6M increase.
  • Rock Springs Capital Management's biggest Q1 2019 reduction was Molina Healthcare, cutting an estimated $18.2M.
  • Rock Springs Capital Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $44.7M.
  • Rock Springs Capital Management's ten largest holdings make up 32% of its $2.59B portfolio in Q1 2019.
  • Rock Springs Capital Management opened 7 new positions and closed 9 in Q1 2019.
  • Rock Springs Capital Management's portfolio value rose 22% quarter-over-quarter to $2.59B.

Based on Rock Springs Capital Management's 13F filing for Q1 2019, filed 15 May 2019.